Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Elizabeth K. Bancroft1,2, Elizabeth C. Page2, Elena Castro2,3, Hans Lilja4,5,6,7, Andrew Vickers8, Daniel Sjoberg8, Melissa Assel8, Christopher S. Foster9, Gillian Mitchell10,11, Kate Drew10, Lovise Mæhle12, Karol Axcrona12, D. Gareth Evans13, Barbara Bulman13, Diana Eccles14, Donna McBride14, Christi van Asperen15, Hans Vasen16, Lambertus A. Kiemeney17, Janneke Ringelberg16
1Cancer Genetics Unit and Academic Urology Unit, Royal Marsden NHS Foundation Trust, London, UK
2Oncogenetics Team, Institute of Cancer Research, London, UK
3Spanish National Cancer Research Centre, Madrid, Spain
4Departments of Laboratory Medicine, Surgery, and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
5Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
6Institute of Biomedical Technology, University of Tampere, Tampere, Finland
7Department of Laboratory Medicine, Lund University, Malmö, Sweden
8Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
9HCA Healthcare Laboratories, London, WC1E 6JA, UK
10Familial Cancer Centre, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
11Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
12Norwegian Radium Hospital, Oslo, Norway
13Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
14Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK
15Leiden University Medical Center, Leiden, The Netherlands.
16Foundation for the Detection of Hereditary Tumours, Leiden, The Netherlands
17Radboud University Medical Centre, Nijmegen, The Netherlands
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
European Urology
Tập 66
489-499
Thông tin tác giả